Photo from Akash Maniam/LinkedIn
Apr 27, 2024, 11:39
Akash Maniam: The optimal management of upper tract urothelial carcinoma is far from clear
Akash Maniam, Medical Oncologist at Portsmouth Hospitals University NHS Trust, shared a post by International Urology Cancer Summit on LinkedIn, adding:
“Great question. The optimal management of upper tract urothelial carcinoma is far from clear. Higher fibroblast growth factor receptors (FGFR) alteration rates, lower immunotherapy response rates, differences in tumour mutational burden/microenvironment etc.
How do you or would you treat this at your centre? Chemotherapy alone, chemotherapy and IO, enfortumab-vedotin/Pembrolizumab
Would you enrol into a clinical trial example targeting Fibroblast growth factor receptor (FGFR) 1st line? Vote and comment, would be an enriching discussion!”
Quoting International Urology Cancer Summit’s post:
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 00:19
Nov 14, 2024, 00:02
Nov 13, 2024, 23:57
Nov 13, 2024, 23:54
Nov 13, 2024, 23:48
Nov 13, 2024, 23:46